ClinicalTrials.gg
RecruitingNCT04113356MARINA-STEMIUpdated Sep 10, 2021

Magnetic Resonance Imaging In Acute ST-Elevation Myocardial Infarction

An observational study in Acute ST-Elevation Myocardial Infarction, sponsored by Medical University Innsbruck. Recruiting at 2 sites in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-10.

Sponsored by Medical University Innsbruck · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jan 2011; still recruiting 15 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in ST Elevation Myocardial Infarction with a site in Austria — 7 open to participants now, 9 under way, none of them phase 3. ST Elevation Myocardial Infarction · Austria.

Started
2011
with 3 others
Observational
9 of 23
5 open now
Registered
14th of 23
by date
Lead sponsor
4 of 23
Medical University Innsbruck

Among the 23 studies in ST Elevation Myocardial Infarction with a site in Austria, this one is one of 4 that started in 2011, is one of 9 observational ones, and was the 14th registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

7 of the 23 studies in ST Elevation Myocardial Infarction with a site in Austria are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in ST Elevation Myocardial Infarction with a site in Austria, or all of them as a file.
02

Study summary

Cardiovascular magnetic resonance imaging enables comprehensive assessment of cardiovascular function, morphology and pathology. The investigators aim to evaluate the nature and clinical significance of magnetic resonance imaging parameters in patients presenting with first acute ST-elevation myocardial infarction.

03

Conditions studied

  • Acute ST-Elevation Myocardial Infarction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with acute ST-elevation myocardial infarction treated with primary percutaneous coronary intervention admitted to the coronary care unit of Innsbruck University Hospital for Internal Medicine III (Cardiology and Angiology).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • First ST-elevation myocardial infarction according to the European Society of Cardiology/American College of Cardiology committee criteria
  • Primary percutaneous coronary intervention within 24 hours after symptom onset

Exclusion criteria

Exclusion criteria:

  • Age \< 18 years
  • Any history of a previous myocardial infarction or coronary intervention
  • Clinically unstable patients (Killip class >2)
  • Renal failure (estimated \< 30 ml/min/1.73 m2)
  • to cardiac magnetic resonance imaging (pacemaker, cerebral aneurysm clip, orbital foreign body, known or suggested contrast allergy to gadolinium, claustrophobia)
  • Inability to provide
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Patient registry
No

Groups and cohorts

  • ST-Elevation Myocardial Infarction

    Patients with acute ST-elevation myocardial infarction treated with primary percutaneous coronary intervention

    Diagnostic Test: Cardiovascular Magnetic Resonance Imaging

Interventions

  • Diagnostic testCardiovascular Magnetic Resonance Imaging

    Cardiovascular magnetic resonance imaging will be performed within the first week after ST-elevation myocardial infarction and in a defined subgroup 4 months, 12 months and 10 years thereafter.

06

What researchers measure

Primary outcomes

  1. Occurence of major adverse cardiovascular events

    Time frame: 1 - 5 years

Secondary outcomes

  1. Infarct size assessment (% of left ventricular myocardial mass)

    Time frame: baseline, 4 months and 12 months

  2. Assessment of infarct transmurality grade (%) with late gadolinium enhancement imaging

    Time frame: baseline, 4 months and 12 months

  3. Occurence and area of microvascular obstruction

    Time frame: baseline

  4. Intramyocardial haemorrhage assessed by T2* imaging

    Time frame: baseline, 4 months and 12 months

  5. Tissue characterisation by T1, T2 and T2* Mapping

    Time frame: baseline, 4 months and 12 months

  6. Myocardial deformation by strain analysis

    Time frame: baseline, 4 months and 12 months

  7. Chamber volumes by cine imaging

    Time frame: baseline, 4 months and 12 months

  8. Cardiac function by cine imaging

    Time frame: baseline, 4 months and 12 months

  9. Stroke volumes by phase contrast imaging

    Time frame: baseline, 4 months and 12 months

  10. Aortic pulse wave velocity and distensibility by phase contrast imaging

    Time frame: baseline, 4 months and 12 months

  11. Aortic pulse wave distensibility by phase contrast imaging

    Time frame: baseline, 4 months and 12 months

  12. Quality of life and invalidity assessment (Global Physical Activity Questionnaire)

    Time frame: 1 - 5 years

  13. Biomarker release during the acute and subacute phase

    biomarker concentrations of hemodynamic stress (n-terminal pro-B-type natriuretic peptide), neurohumoral markers (i.e. neprilysin ng/ml), inflammatory markers (i.e. procalcitonin µg/l) and markers of myocardial injury (i.e. high sensitivity cardiac troponin T ng/l)

    Time frame: baseline, 4 months and 12 months

  14. Parameters of cardiac function by transthoracic echocardiography

    Time frame: baseline, 4 months and 12 months

  15. Plaque volume by 3D ultrasound

    Time frame: baseline, 12 months

  16. Cardiac autonomic function

    Deceleration capacity of heart rate

    Time frame: baseline, 4 months and 12 months

  17. Cardiac autonomic function

    Heart rate variability

    Time frame: baseline, 4 months and 12 months

  18. Cardiac autonomic function

    Periodic repolarization dynamics

    Time frame: baseline, 4 months and 12 months

  19. Cardiac autonomic function

    Baroreflex sensitivity

    Time frame: baseline, 4 months and 12 months

  20. Cardiac autonomic function

    Skin sympathetic nerve activity

    Time frame: baseline, 4 months and 12 months

07

Study locations

2 of 2 sites recruiting
  • University Hospital for Internal Medicine III (Cardiology and Angiology)
    Innsbruck, 6020, Austria
    Recruiting
    • Bernhard Metzler, MD, MSc · Contactbernhard.metzler@tirol-kliniken.at
    • Gert Klug, MD · Sub investigator
    • Sebastian Johannes Reinstadler, MD, PhD · Sub investigator
    • Martin Reindl, MD, PhD · Sub investigator
    • Christina Tiller, MD, PhD · Sub investigator
    • Magdalena Holzknecht, MD · Sub investigator
    • Ivan Lechner, MD · Sub investigator
    • Priscilla Fink, MD · Sub investigator
  • University Hospital for Radiology
    Innsbruck, 6020, Austria
    Recruiting
    • Agnes Mayr, MD · Contacta.mayr@i-med.ac.at
    • Agnes Mayr, MD · Sub investigator
    • Mathias Pamminger, MD · Sub investigator
08

References and documents

Publications

  • Holzknecht M, Tiller C, Reindl M, Lechner I, Fink P, Lunger P, Mayr A, Henninger B, Brenner C, Klug G, Bauer A, Metzler B, Reinstadler SJ. Association of C-Reactive Protein Velocity with Early Left Ventricular Dysfunction in Patients with First ST-Elevation Myocardial Infarction. J Clin Med. 2021 Nov 24;10(23):5494. doi: 10.3390/jcm10235494. PubMed 34884196 ↗
  • Tiller C, Reindl M, Holzknecht M, Lechner I, Schwaiger J, Brenner C, Mayr A, Klug G, Bauer A, Metzler B, Reinstadler SJ. Association of plasma interleukin-6 with infarct size, reperfusion injury, and adverse remodelling after ST-elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2022 Feb 8;11(2):113-123. doi: 10.1093/ehjacc/zuab110. PubMed 34849677 ↗
  • Lechner I, Reindl M, Tiller C, Holzknecht M, Niederreiter S, Mayr A, Klug G, Brenner C, Bauer A, Metzler B, Reinstadler SJ. Determinants and prognostic relevance of aortic stiffness in patients with recent ST-elevation myocardial infarction. Int J Cardiovasc Imaging. 2022 Jan;38(1):237-247. doi: 10.1007/s10554-021-02383-0. Epub 2021 Sep 2. PubMed 34476665 ↗
  • Reindl M, Lechner I, Tiller C, Holzknecht M, Rangger A, Mayr A, Theurl M, Klug G, Brenner C, Bauer A, Metzler B, Reinstadler SJ. Glycemic Status and Reperfusion Injury in Patients With ST-Segment Elevation Myocardial Infarction. JACC Cardiovasc Imaging. 2021 Sep;14(9):1875-1877. doi: 10.1016/j.jcmg.2021.04.007. Epub 2021 May 19. No abstract available. PubMed 34023265 ↗
  • Reindl M, Tiller C, Holzknecht M, Lechner I, Eisner D, Riepl L, Pamminger M, Henninger B, Mayr A, Schwaiger JP, Klug G, Bauer A, Metzler B, Reinstadler SJ. Global longitudinal strain by feature tracking for optimized prediction of adverse remodeling after ST-elevation myocardial infarction. Clin Res Cardiol. 2021 Jan;110(1):61-71. doi: 10.1007/s00392-020-01649-2. Epub 2020 Apr 15. PubMed 32296969 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2011 (actual). Primary completion is estimated for Jun 2026, 185 months after the start.

Of 122 non-industry observational studies under ST Elevation Myocardial Infarction, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 107. This study's planned 185 months is above that.

Counting every sponsor, half of 143 studies reached it within 38 months; a quarter within 21 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2019
First posted
Oct 2, 2019
StartActual
Jan 2011
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2031
Last update
Sep 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04113356
Responsible party
Sponsor
First posted
Oct 2, 2019
Start date
Jan 2011
Primary completion
Jun 2026 (estimated)
Completion
Jun 2031 (estimated)
Last update
Sep 10, 2021

Study contacts

Bernhard Metzler, MD, MSc
Contact
bernhard.metzler@tirol-kliniken.at
Gert Klug, MD
Contact
gert.klug@tirol-kliniken.at
Bernhard Metzler, MD, MSc
principal investigator · University Hospital for Internal Medicine III (Cardiology and Angiology)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion